아울러 '세계 최초 치료제' 등 중요한 신약은 특별심사팀을 만들어 집중관리하고 교차 검증하겠다는 방침도 밝혔다.
In addition, it also revealed a policy to intensively manage and cross-verify important new drugs such as "the world's first treatment" by creating a special evaluation team.